TauRx' anti-tau could be safer disease-modifying therapy for Alzheimer's

Singapore-based TauRx Pharmaceuticals, a company that claims to be the global leader in tau-based research in Alzheimer’s disease, recently reported positive progress for the firm's lead investigative oral drug hydromethylthionine mesylate (HMTM). The drug was found to be effective in improving cognition in patients with early Alzheimer’s disease (AD).

TauRx now plans to submit HMTM for regulatory approval in the USA and Canada in 2023, with other territories to follow, in line with its overall plans to commercialize HMTM and pursue clinical trials in other related neurodegenerative diseases.

Reviewing the situation, pharma analytic firm GlobalData’s senior neurology analyst Pippa Salter said: “A key unmet need in the AD market is for the development of disease-modifying therapies (DMTs) that can stop or even reverse the disease. Historically, the amyloid hypothesis has dominated the AD space, however, with multiple failures of amyloid-targeting drug candidates, the focus has widened to include anti-tau therapies.